In a phase I study in women’s cancers (ovarian, triple negative breast (TNBC), cervical and uterine), Lee et al. evaluated the anti-PD-L1 antibody durvalumab in combination with olaparib in 12 patients (10 had ovarian cancer and 2 had TNBC), 11 of which were BRCA wild type (BRCAwt) and 1 was unknown. This evidence concerns the gene CD274 and ovarian carcinoma.